Early PET May Help Tailor Therapy in Hodgkin Lymphoma

Published Date: 13 May 2026

A trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.

Read Full News

Latest News

Annual Cancer Report Highlights Advances, Funding Threats

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

Does Telenursing Improve QOL in Breast Cancer?

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

Long-Term Results Favor Acalabrutinib Combo in MCL

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

First-Line Combo Therapies Best Chemo Alone in NSCLC Trials

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

3D Mammography Improves Long-Term Cancer Risk Prediction

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Osimertinib's OS Benefit in Resected NSCLC Persists 8 Years

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

Todays Updates

Benign or Malignant? No Way to Tell Radiologically

Case shows importance of accurate preop diagnosis

FDA Advisors Recommend Galleri Multicancer Blood Test

Some panelists had reservations about the test's true benefit, however

FDA Approves New Option for Previously Treated Bile Duct Cancer

— Trial of lirafugratinib showed responses in almost half of patients, with good durability

Todays Updates

Benign or Malignant? No Way to Tell Radiologically

Case shows importance of accurate preop diagnosis

FDA Advisors Recommend Galleri Multicancer Blood Test

Some panelists had reservations about the test's true benefit, however

FDA Approves New Option for Previously Treated Bile Duct Cancer

— Trial of lirafugratinib showed responses in almost half of patients, with good durability

Latest News

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

News All Time

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

A New PARADIGM? Azacitidine-Venetoclax Tops Chemo in AML

The less-intensive drug combination outperforms standard induction chemotherapy in fit patients with acute myeloid leukemia.

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

Talc Powder Not Linked to Lung Cancer in Women

A study of US women finds no connection between talc powder use and lung cancer, though subgroup findings leave questions open.

Saturated Fat Tied to Worse Survival After Prostate Cancer

The association is driven by higher rates of death from cardiovascular disease and other cancers over 13 years.

Medication Self-Injection Embraced by Breast Cancer Patients

Women with breast cancer show interest in self-injecting their medication.

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

Low Awareness of How to Spot Rare Breast Cancer Identified

Researchers survey US adults to assess their knowledge of inflammatory breast cancer.

Remote CBT for Insomnia Improves Symptoms During Chemo

A new randomized trial strengthens the case for managing cancer-related insomnia with cognitive-behavioral therapy.

Long-Acting Interferon Therapy Approved for ET

Ropeginterferon alfa-2b is designed to provide durable disease control.

Thymus Radiation Exposure Tied to Worse Lung Cancer Outcomes

The thymus is not routinely considered during thoracic radiotherapy planning, but new findings suggest that may need to change.

FDA Approves Rusfertide for Polycythemia Vera

Adding rusfertide to standard-of-care treatment cut phlebotomy rates by more than half in the phase 3 VERIFY trial.

Black Canadians Face Multiple Barriers to Blood Donation

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Recommended News For You

Opposition to the Surgical Lymph Node Sampling Rule for Lung Resection.

Early PET May Help Tailor Therapy in Hodgkin Lymphoma

Pancreatic Cancer: A Novel CD40 Agonist-Chemo Combo Shows Promise.

Medical debt in collections persists after cancer diagnosis

Compared to previous estimates, a greater number of patients participate in cancer treatment trials.

Independent Risk Factors for "Deaths of Despair" Found.

Progress in Early Cancer Diagnosis; Breast Cancer in Younger Women; Diet and Cancer.

Recommended Articles For You

Radiation Oncology: Integrating AI, Theranostics, and Adaptive Therapies for Personalized Cancer Care 

Acrochordon: What It Is, Causes, And How To Manage This Skin Condition 

Drug Safety Through Oncology Survivorship Medication Monitoring Frameworks 

Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

It Is Not Just the Royals Who Go Through Cancer.

2.

Laryngeal Transplant Helped a Cancer Patient Speak Again in Pioneering Study

3.

New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show

4.

Annual whole-body, low-dose CT aids management of smoldering multiple myeloma

5.

Children with the "Failure to Launch" Syndrome in Adulthood Have New Hope.

1.

Tumor Microenvironment Reprogramming for Regenerative Cancer Recovery

2.

A Review on Genetic Predispositions and Clinical Advancements of Multiple Myeloma Cancer

3.

Rasburicase-Linked Methemoglobinemia in HCC: Risks, Mechanisms, and Management

4.

Exercise Rehabilitation in Hematologic Disease Survivorship

5.

Unlocking the Mystery of Granulomas: A Closer Look at the Causes and Treatment

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

1.

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity

2.

Exploring the Hospitalization Burden in Refractory and Relapsed ALL

3.

Navigating the Complexities of Ph Negative ALL - Part VIII

4.

Current Scenario of Cancer- Q&A Session to Close the Gap

5.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot